NAD+ and Longevity: What the Research Actually Shows in 2026

NAD+ is having a moment. From Silicon Valley biohackers to anti-aging clinics, it's become one of the most talked-about molecules in longevity medicine. IV drips, sublingual tablets, liposomal formulas, skin patches — there's no shortage of ways to take it and no shortage of claims about what it does.

But beneath the marketing is a molecule with genuinely compelling science. Understanding what that science actually shows — and what it doesn't — is important for making informed decisions about whether NAD+ therapy makes sense for you.

What NAD+ Is and Why It Declines With Age

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell in the human body. It's essential for:

Cellular energy production: NAD+ is the critical electron carrier in the mitochondrial electron transport chain. Without it, cells cannot produce ATP efficiently. Everything you do — every muscle contraction, every thought, every heartbeat — depends on cellular energy production that requires NAD+.

Sirtuin activation: Sirtuins are a family of proteins with profound roles in aging, DNA repair, and metabolic regulation. Sirtuins consume NAD+ as a substrate. Low NAD+ = reduced sirtuin activity = reduced DNA repair, impaired metabolic regulation, and accelerated cellular aging markers.

PARP enzymes (DNA repair): PARP-1 is a critical DNA repair enzyme that uses NAD+ as a substrate. DNA damage accumulates with age; without adequate NAD+, repair mechanisms are impaired.

Mitochondrial function: Beyond the electron transport chain, NAD+ affects mitochondrial biogenesis (creation of new mitochondria) and mitophagy (clearance of dysfunctional mitochondria). Both processes are critical for cellular health.

The problem: NAD+ levels decline by approximately 50% between ages 20 and 50, and continue declining with age. This decline is observed across tissues — muscle, liver, brain, and blood. And this decline correlates with exactly the changes we associate with aging: reduced energy, worse metabolic function, slower recovery, impaired DNA repair.

This isn't correlation without mechanism. The causal pathway is well-established in cellular biology.

The Animal Data: Remarkable

The anti-aging evidence for NAD+ restoration is most robust in animal studies, which form the mechanistic foundation for the human work.

In multiple mouse studies: - NMN or NR supplementation improved mitochondrial function, energy metabolism, and physical performance in aged mice - NAD+ restoration reversed some age-associated muscle loss (sarcopenia) - In Alzheimer's disease mouse models, NAD+ precursors reduced amyloid and tau pathology - Lifespan extension has been demonstrated in C. elegans (roundworms) and some mouse models - NAD+ restoration improved insulin sensitivity and metabolic function in high-fat diet mouse models

These aren't fringe findings — they've been replicated across multiple research groups including David Sinclair's lab at Harvard, Johan Auwerx's lab in Switzerland, and several others.

The Human Data: Promising but Still Early

Human clinical trials with NAD+ precursors are an active area of research. The evidence is promising, but more limited than the animal data:

Muscle and exercise: A 2023 randomized trial in older adults showed that NMN supplementation (250mg/day for 12 weeks) combined with exercise training improved aerobic capacity (VO2 max) more than exercise alone. Muscle NAD+ levels increased. The combination effect suggests NAD+ may amplify training adaptations.

Blood NAD+ levels: Multiple human trials have confirmed that oral NMN and NR supplementation reliably increases blood NAD+ levels. This is a necessary prerequisite but not sufficient evidence of clinical benefit.

Metabolic effects: Studies in overweight/obese adults have shown improvements in insulin sensitivity with NR supplementation. A 2020 trial published in Nature Communications showed NR raised NAD+ in blood and skeletal muscle of overweight but otherwise healthy men and women.

Cognitive function: Emerging trials in patients with mild cognitive impairment are studying NAD+ precursors. No large completed trials yet, but the mechanistic rationale (NAD+-dependent DNA repair, neuronal energy metabolism, sirtuin effects on neurodegeneration pathways) is compelling.

IV NAD+: The IV route raises blood NAD+ levels rapidly and is the delivery method used in clinical settings for more aggressive NAD+ restoration. Patient reports consistently describe improved energy, mental clarity, and in some cases mood during and after infusions. Controlled clinical trials specifically on IV NAD+ are less numerous than oral precursor trials.

The Delivery Question: IV vs. Oral

Understanding why delivery method matters requires understanding NAD+ metabolism.

When you take oral NMN or NR: 1. It's absorbed in the gut 2. Converted to NAD+ through enzymatic steps in cells 3. Distributed to tissues where conversion happens

This process is reasonably efficient — oral NMN and NR do raise tissue NAD+ levels in humans. But the conversion is rate-limited by enzymes, the amount absorbed varies, and peak tissue levels take time to build.

IV NAD+ bypasses all of this: 1. Delivered directly to bloodstream 2. Immediately available to tissues 3. Rapid, high peak levels

For patients seeking aggressive NAD+ restoration — or in clinical settings like addiction medicine where NAD+ infusions have been used for decades — the IV route provides faster, more reliable elevation. The common "buzzing" sensation during IV NAD+ infusions is real and is attributed to the rapid cellular uptake of the coenzyme.

What NAD+ Does NOT Do

Being clear-eyed about evidence means acknowledging what hasn't been proven:

Not a proven anti-aging therapy: There are no long-term human studies showing that NAD+ precursors extend human lifespan or definitively prevent age-associated disease. The animal data is compelling; the human data is preliminary.

Not a stand-alone intervention: NAD+ functions within a complex cellular environment. Sleep deprivation, poor diet, lack of exercise, and chronic inflammation all deplete NAD+ and override supplementation benefits. NAD+ doesn't compensate for fundamentally unhealthy lifestyle patterns.

Not universally effective: Some individuals have genetic variants in NAD+ synthesis and degradation pathways that affect how they respond to supplementation. Response is variable.

Not proven for any specific disease (in humans): While the mechanistic case for NAD+ in neurodegeneration, metabolic disease, and cancer prevention is strong, the human clinical evidence for specific disease outcomes is still developing.

Who Makes the Best Candidate

Based on the existing evidence, NAD+ therapy is most likely to produce meaningful benefit in:

Adults over 40: NAD+ decline is most significant in this range, and the gap between where levels are and where they should be is largest. Restoring levels has more room to make a difference.

Those with metabolic dysfunction: Insulin resistance, obesity, and metabolic syndrome are associated with accelerated NAD+ depletion. The metabolic improvements from NAD+ restoration are particularly relevant for this group.

Athletes and high-performance individuals: The exercise trial data, combined with NAD+'s role in energy metabolism and recovery, makes it a reasonable addition to a performance optimization stack — particularly for those training seriously.

Patients with chronic fatigue or energy complaints: If cellular energy production is genuinely compromised, NAD+ restoration addresses a real mechanism. This isn't placebo territory; it's addressing actual metabolic physiology.

The Marrow Approach to NAD+

NAD+ therapy at Marrow is positioned as what it actually is: a longevity and metabolic optimization protocol with genuinely compelling science at the cellular level, emerging human evidence, and a safety profile that's excellent.

We don't oversell it as a guaranteed anti-aging intervention. We don't undersell the real mechanistic evidence. The honest answer is: the biology is solid, the early human evidence is promising, and for patients who are serious about metabolic optimization, it's one of the more scientifically justified longevity interventions available.

The Bottom Line

NAD+ is not snake oil. The cellular science is robust, the animal data is remarkable, and the early human data is genuinely promising. But human clinical evidence — particularly for longevity outcomes — is still developing. What's proven: NAD+ declines with age, that decline impairs fundamental cellular functions, and restoring levels through supplementation or IV therapy raises both NAD+ and measurable markers of cellular function.

For patients over 40 who are serious about metabolic health and longevity, NAD+ therapy represents one of the more scientifically grounded interventions in the current longevity toolkit. Go in with realistic expectations — not as a miracle molecule, but as a cellular foundation that supports the other things you're doing for your health.